Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520686 · ClinicalTrials.gov registry record · Phase 3
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by ImmunityBio.
- Active
- Registry status
- Phase 3
- Development phase
- 1,538
- Enrollment target
- 20
- Study locations
NCT03520686 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by ImmunityBio. The registered enrollment target is 1,538 participants, above the 655-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (135% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03520686, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by ImmunityBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,538 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG NAI + Pembrolizumab
- DRUG NAI + Nivolumab + Ipilimumab
- DRUG NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel
- DRUG Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice)
Study Locations (20)
California
- Chan Soon-Shiong Institute for Medicine - El Segundo
- Adventist Health Glendale - Glendale
- MemorialCare Health System - Long Beach
- Adventist Health White Memorial - Los Angeles
- Hoag Memorial Hospital - Newport Beach
- Desert Hematology Oncology Medical Group - Rancho Mirage
Florida
- Memorial Healthcare - Hollywood
- Baptist Health South Florida - Miami Cancer Institute - Miami
Kentucky
- Baptist Health - Lexington - Lexington
- Baptist Health Louisville - Louisville
New York
- University of Rochester - Rochester
- Stony Brooke Medicine - Stony Brook
Alaska
- Alaska Urological Institute - Alaska Clinical Research Center - Anchorage
Arkansas
- Genesis Cancer Center - Hot Springs
Illinois
- Healthcare Research Network - Tinley Park
Michigan
- Karmanos Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,538 participants |
| Start Date | 2018-05-18 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520686
The ClinicalTrials.gov registry entry for NCT03520686 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,538 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 655-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (135% higher). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03520686 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03520686 about?
NCT03520686 is a clinical study titled "Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer". This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed p...
What is the current status of trial NCT03520686?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2018-05-18. Estimated completion is 2026-12-31.
What conditions does trial NCT03520686 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03520686?
The interventions under investigation include: Pembrolizumab (DRUG), NAI + Pembrolizumab (DRUG), NAI + Nivolumab + Ipilimumab (DRUG), NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (DRUG), Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) (DRUG).
Who is sponsoring clinical trial NCT03520686?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03520686 being conducted?
This trial has 20 study locations across Alaska, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.